Pfizer's Sutent improves survival without surgery

Data from the Phase III CARMENA trial evaluating Sutent sunitinib from Pfizer Inc. (NYSE:PFE) showed that patients with renal cell carcinoma could avoid nephrectomy without compromising survival. The data were presented Sunday at the

Read the full 348 word article

User Sign In